Irene Ferrer
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 25, 2025
The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.
Journal: EMBO molecular medicine
Published: February 17, 2025
Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion.
Journal: Clinical and translational medicine
Published: December 04, 2024
CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer.
Journal: Signal transduction and targeted therapy
Published: September 02, 2024
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts.
Journal: Oncoimmunology
Published: August 29, 2024
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum.
Journal: EMBO molecular medicine
Published: July 25, 2024
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.
Journal: Nature communications
Published: March 02, 2024
Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.
Journal: International journal of molecular sciences
Published: August 21, 2023
High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.
Journal: Nature communications
Published: April 26, 2023
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Journal: Nature communications
Published: December 13, 2022
Last Updated: 09/26/2026